Head-to-head evidence
Alimatravir vs Tenofovir alafenamide/emtricitabine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Alimatravir
Developed by Merck & Co.
NCT06045507 · Phase 2 · completed
The study randomized 352 participants to three MK-8527 dose groups or matched placebo and used double blinding, but Alimatravir was not studied and was not the comparator. Its primary endpoints were safety outcomes rather than efficacy, and the registry provides counts without statistical comparisons, so whether the primary comparisons were met cannot be determined.
Next expected readout: January 2027 · NCT07600775 (registry estimate)
Tenofovir alafenamide/emtricitabine · Descovy
Marketed by Gilead Sciences
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07349758 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alimatravir's landscape · Tenofovir alafenamide/emtricitabine's landscape